CClinicalTrials.gg
RecruitingNCT07433751ECHO-MACROUpdated Jun 16, 2026

Ultrasound Estimation of Fetal Macrosomia at Term: Diagnostic Accuracy Within 24 Hours of Delivery

An interventional study of Ultrasound estimation of fetal macrosomia at 12 weeks of amenorrhea and Ultrasound estimation of fetal macrosomia at 22 weeks of amenorrhea in Macrosomia and Fetal Weight, sponsored by Centre Hospitalier Henri Duffaut - Avignon. Recruiting at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Centre Hospitalier Henri Duffaut - Avignon · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
285
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Obstetric ultrasonography is now an essential tool for monitoring pregnancy. In France, three ultrasounds are recommended during a singleton pregnancy (at 12, 22, and 32 weeks of amenorrhea) to improve maternal and neonatal care. Among the parameters studied, fetal weight estimation allows for the assessment of fetal growth and the detection of certain conditions such as intrauterine growth restriction or macrosomia.

Fetal weight estimation is based primarily on the Hadlock formula, which combines several biometric measurements (head circumference, abdominal circumference, and femur length). This estimate has a margin of error of 6 to 10% compared to birth weight, which is still accurate enough to guide important medical decisions, such as inducing labor or performing a cesarean section. However, an estimation error can have negative consequences for both mother and child.

Fetal macrosomia is defined as a birth weight greater than or equal to 4000 g. It affects approximately 5 to 10% of pregnancies. Screening is mainly based on ultrasound, particularly in the second and third trimesters.

Macrosomia is associated with an increased risk of complications for the mother (cesarean section, postpartum hemorrhage, or deep vein thrombosis) and the child (shoulder dystocia, fractures, brachial plexus palsy, or neonatal asphyxia). These risks are increased in cases of macrosomia in the context of maternal diabetes.

Within the gynecology-obstetrics department, physicians use the protocole of macrosomia screening described in the DAME trial. If macrosomia is suspected an additional ultrasound is performed at around 36 weeks of amenorrhea. The Hadlock formula is used to estimate fetal weight. The ultrasound criteria for suspecting macrosomia are an estimated fetal weight above the 95th percentile (90th percentile in cases of maternal diabetes) according to WHO curves. In these cases, induction is offered between 38 and 39 weeks of amenorrhea, if the cervix is favorable. A cesarean section is offered to the patient if the estimated fetal weight is greater than 5000 g in the absence of diabetes and greater than 4500 g in cases of associated diabetes.

Nevertheless, the probability of a child being born macrosomic after ultrasound suspicion is between 17% and 80% on average, and 53% in our center. Although beneficial in the context of macrosomia, the effects of induced labor or cesarean delivery are not insignificant for the mother and her baby. In this context, the value of this study is to demonstrate that performing an ultrasound as close to the birth as possible could allow for a more reliable estimation of fetal weight and better detection of macrosomia in order to avoid unnecessary procedures.

The investigators hypothesize that fetal weight estimation is more accurate when performed within 24 hours prior to delivery. When the assessment is conducted earlier, it inherently assumes a constant fetal growth rate until birth, which may not reflect actual growth patterns. A more precise estimation of birth weight could improve clinical decision-making and optimize maternal and neonatal care, potentially reducing unnecessary interventions such as labor induction or cesarean delivery.

02

Conditions studied

  • Macrosomia
  • Fetal Weight

Browse trials for

Keywords

  • Macrosomia
  • Fetal weight
  • Ultrasound
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age ≥ 18 years old.
  • Patient with suspected fetal macrosomia above the 95th percentile, or above the 90th percentile in the case of maternal diabetes, according to Hadlock's formula and WHO charts, during the third-trimester ultrasound (between 32 and 34 weeks of amenorrhea).
  • Female patient presenting for a follow-up ultrasound at 36 ± 1 weeks of amenorrhea due to suspected macrosomia.
  • Singleton pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Fetal weight estimation at 36 ± 1 weeks of amenorrhea and macrosomia assessment performed outside of the hospital.
  • Patient with uncertain gestational age.
  • Patient with a multiple pregnancy
  • Presence of detectable morphological or chromosomal abnormalities.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Group 1

    Macrosomia confirmed by ultrasound at 36 weeks

    Diagnostic Test: Ultrasound estimation of fetal macrosomia at 12 weeks of amenorrhea · Diagnostic Test: Ultrasound estimation of fetal macrosomia at 22 weeks of amenorrhea · Diagnostic Test: Ultrasound estimation of fetal macrosomia at 32 weeks of amenorrhea · Diagnostic Test: Ultrasound estimation of fetal macrosomia before birth

  • Other
    Group 2

    Macrosomia not confirmed by ultrasound

    Diagnostic Test: Ultrasound estimation of fetal macrosomia at 12 weeks of amenorrhea · Diagnostic Test: Ultrasound estimation of fetal macrosomia at 22 weeks of amenorrhea · Diagnostic Test: Ultrasound estimation of fetal macrosomia at 32 weeks of amenorrhea

Interventions

  • Diagnostic testUltrasound estimation of fetal macrosomia at 12 weeks of amenorrhea

    Ultrasound estimation of fetal macrosomia at 12 weeks of amenorrhea (estimated weight according to the Hadlock formula and WHO growth charts)

  • Diagnostic testUltrasound estimation of fetal macrosomia at 22 weeks of amenorrhea

    Ultrasound estimation of fetal macrosomia at 22 weeks of amenorrhea (estimated weight according to the Hadlock formula and WHO growth charts)

  • Diagnostic testUltrasound estimation of fetal macrosomia at 32 weeks of amenorrhea

    Ultrasound estimation of fetal macrosomia at 32 weeks of amenorrhea (estimated weight according to the Hadlock formula and WHO growth charts)

  • Diagnostic testUltrasound estimation of fetal macrosomia before birth

    Ultrasound estimation of fetal macrosomia within 24 hours ± 6 hours, prior to birth (estimated weight according to the Hadlock formula and WHO growth charts)

05

What researchers measure

Primary outcomes

  1. Frequency of fetal macrosomia

    Frequency will be expressed as numbers and percentages

    Time frame: 24 hours before birth

Secondary outcomes

  1. Assess the diagnostic performance of the different ultrasound examinations for the detection of fetal macrosomia at birth.

    By analyzing true-positive, false-positive, true-negative, and false-negative rates in a 2x2 contigency table

    Time frame: At birth

06

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier d'Avignon, Hôpital Henri Duffaut
    Avignon, 84000, France
    • Marilyne Grinand, PhD · Contact · grinand.marilyne@ch-avignon.fr · (+33)0432759392
    • Jean-Yves Col, MD · Principal investigator
    • Sonia Rasolofomanana, MD · Sub investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07433751
Lead sponsor
Centre Hospitalier Henri Duffaut - Avignon
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Apr 8, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Jun 16, 2026

Study contacts

Marilyne Grinand, PhD
Contact
grinand.marilyne@ch-avignon.fr
(+33)432759392

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion